September 14, 2015 |
For researchers, physicians - and patients - prostate cancer has always been among the most maddening and elusive of foes. The third-most common cancer in the United States, behind breast and lung cancers, its course is less predictable than either. It can remain dormant in a man's body until he dies decades later from something else. Or it can spread aggressively and kill. The riddle has been how to tell one cancer from another. Now researchers at Thomas Jefferson University and elsewhere think they are coming closer to solving it through increasingly sophisticated genetic studies.
October 9, 2014 |
Michael Milken, the long-retired 1980s junk-bond king and now big-time prostate cancer philanthropist, blew into the Wanamaker's Crystal Tea Room on Tuesday evening for one of the city's bigger and faster-growing charitable events. He jets around the nation to about 100 of these events a year, flying into Philadelphia on Tuesday from Dallas and planning to immediately depart Philadelphia for Washington. "I see light at the end of the tunnel," Milken said of cancer cures, adding that he believed philanthropists like those in Philadelphia had to support young scientists as the federal government has curtailed medical-research funding in recent years.
October 8, 2014 |
More than a decade after prostate cancer became the economic driver behind proton beam therapy in the U.S., it still isn't clear that men treated with the technology do better than those who get less costly radiation treatments. That's why expert groups have recently advised against insurance coverage of proton therapy for prostate cancer - and why some private plans are refusing to pay for it. The Catch-22 is that this pullback is hampering a clinical trial co-led by the University of Pennsylvania that would finally settle the question of superiority.
September 16, 2014 |
Kristine Warner wanted an eye-catching way to encourage men to talk to their doctors about the complicated, controversial subject of prostate cancer screening. Don't Fear The Finger campaign was born. Go ahead and snicker. It got your attention. The finger in question, of course, is the one a physician puts up a man's rectum to feel for cancer in his prostate gland. The rectal exam is usually paired with a PSA blood test. Warner, a graphic designer, former lobbyist, and urologist's daughter, is the volunteer director of the Pennsylvania Prostate Cancer Coalition.
July 16, 2014 |
Two new prostate cancer studies have found that many low-risk patients have been receiving more treatment than is needed or helpful - racking up millions of dollars in excess health-care costs and, potentially, causing more physical harm than good. One of the studies, both of which were published Monday in JAMA Internal Medicine, showed that among patients whose cancer was not aggressive, those who received hormone therapy as their primary treatment did not live any longer than those who were merely carefully monitored.
December 5, 2013 |
The family of a University of Pennsylvania neuroscientist who died of brain cancer sued the university Tuesday, alleging that the school bore responsibility for his death by failing to protect him from laboratory radiation. The family of Jeffrey H. Ware further alleged that Penn physicians enrolled him in a study without proper consent, treating his gliosarcoma with still more radiation, thereby subjecting him to painful side effects long after there was any hope of recovery. Ware, who died in October 2011 at age 47, lived in Haddonfield.
October 2, 2013 |
Decades after lumpectomy became a standard option for women with breast cancer, men are seeking a similarly targeted approach to prostate cancer, one that gets rid of the tumor while preserving the organ. This sensible tack has lagged in prostate cancer for many reasons, starting with the fact that the golf-ball-size gland is inaccessible. It lies deep within the pelvic cavity, surrounded by sensitive structures that are vital to sexual and urinary health. Now, however, an array of technologies is enabling doctors to visualize and zap away prostate malignancies.
August 11, 2013 |
Holy mackerel! Or, in light of a new study, "unholy" might be more appropriate. Omega-3 fatty acids derived from oil in fatty fish like mackerel, tuna, and salmon are still endorsed by doctors for controlling blood fats in heart disease. But when it comes to preventing cancer, the verdict has gotten murky. A study published in July found omega-3 may raise the risk of prostate cancer. "This is not a happy finding," said Theodore Brasky, who led the study at the Ohio State University Comprehensive Cancer Center.
June 18, 2013
In the Region Campbell buys Danish cookie-maker Campbell Soup Co. said it reached an agreement to buy the maker of the popular Royal Dansk Danish butter cookies sold in round blue tins. The price the Camden company agreed to pay for Kelsen Group A/S , which is based in Nørre Snede, Denmark, and sells cookies in 85 countries, was not disclosed. Kelsen had $180 million in net sales last year and employs 366, Campbell said. Highlighting Kelsen's presence in China, Campbell's chief executive Denise Morrison said in a news release that the deal would help Campbell toward its goal of reaching "new consumers through expansion into higher-growth spaces, including fast-growing emerging markets.
May 9, 2013 |
A new genetic test to gauge the aggressiveness of prostate cancer may help tens of thousands of men each year decide whether they need to treat their cancer right away or can safely monitor it. The new test, which goes on sale Wednesday, joins another one that recently came on the market. Both analyze multiple genes in a biopsy sample and give a score for aggressiveness, similar to tests used now for certain breast and colon cancers. Doctors say tests like these have the potential to curb a major problem in cancer care - overtreatment.